Blockade of osteoclast (OC) activity efficiently decreases tumor burden as well as associated bone erosion in immune-compromised animals bearing human osteolytic cancers. In this study, we showed that modulation of antitumor T-cell responses alters tumor growth in bone, regardless of OC status, by using genetic and pharmacologic models. PLCg2 À/À mice, with dysfunctional OCs and impaired dendritic cell (DC)-mediated T-cell activation, had increased bone tumor burden despite protection from bone loss. In contrast, Lyn À/À mice, with more numerous OCs and a hyperactive myeloid population leading to increased T-cell responses, had reduced tumor growth in bone despite enhanced osteolysis. The unexpected tumor/bone phenotype observed in PLCg2 À/À and Lyn À/À mice was transplantable, suggesting the involvement of an immune component.
Introduction
Bone metastases represent a serious complication of many cancers, including breast, prostate, and lung tumors, as well as multiple myeloma. In the bone marrow (BM), there is a mutually positive interaction between osteoclasts (OC) and cancer cells that is known as the vicious cycle (1) . Growth factors secreted by the tumor cells, such as receptor activator of NF-kB-ligand (RANKL), stimulate the bone resorptive activity of OCs. In turn, bone-stored factors including TGFb are released and enhance tumor growth (1) . Experimental evidence suggests that OCs play a central role in modulating the tumor/bone vicious cycle. Antagonism of RANKL, by using recombinant osteoprotegerin (Fc-OPG) or soluble anti-RANKL antibody (Ab), reduces OC number and significantly decreases tumor burden in murine models of breast cancer bone metastasis and multiple myeloma (2) . Similarly, treatment with zoledronic acid (ZOL), an N-bisphosphonate compound highly effective in inducing OC apoptosis and suppressing bone resorption, protects mice injected with human breast cancer cells from developing tumor growth in bone (3) . Based on these findings, the OC is now the principal therapeutic target for bone metastases (4). However, not all patients with bone metastases respond well to antiresorptive therapy, and one third develops further skeletal-related events within 2 years of initiating these therapies (5) . Thus, the results from clinical studies suggest that other bone marrow-residing cells, in addition to OCs, could be regulating tumor growth in bone.
The bone microenvironment is a reservoir of several immune cell types. Memory T cells have been found in the bone marrow of patients with breast cancer, implicating them in cancer immune surveillance (6) . Interestingly, some of the therapies aimed at disrupting the mutual interaction between cancer cells and OCs also have immunomodulatory effects. For example, TGF-b, which is released into the bone marrow microenvironment by the resorptive OC, inhibits T-cell proliferation, natural killer (NK) cell function, and antigen presentation (7) . Thus, blockade of TGF-b at sites of metastases may locally activate T-cell function, initiating an antitumor immune response. ZOL, in addition to its antiresorptive effect, can activate cytotoxic g/d-T cells (8) and inhibit certain populations of myeloid-derived cells with T-cell-suppressor abilities. Unfortunately, to date, the contribution of T cells in modulating the tumor/bone vicious cycle has not been evaluated because most models of bone metastases use human breast cancer cells injected into immunocompromised mice.
The present study aimed to examine the relative contribution of immune cells and OCs in the tumor/bone vicious cycle by using a syngenic mouse model. We turned to the B16 melanoma model of bone metastases because these cells: (i) grow in C57BL/6 immunocompetent mice, and (ii) metastasize to bone following intracardiac injection. B16 is a relatively poorly immunogenic cell line, although it can induce a modest, but specific, T-cell response (9) . Thus, by using B16 cells we can take advantage of genetically manipulated mice with specific immune phenotypes. Phospholipase C gamma (PLCg) 2 is an enzyme converting phosphatidylinositol 4,5-bisphosphate (PIP2) into diacylglycerol (DAG) and inositol triphosphate (IP3) leading to activation of protein kinase C (PKC) and calcium pathways. PLCg2 À/À mice have broadly compromised immune responses due to impaired B-cell development, NK-cell cytotoxic activity, and dendritic cell (DC)-mediated antigen presentation leading to defective T-cell activation (10) (11) (12) (13) . Furthermore, PLCg2 À/À mice are osteopetrotic due to reduced OC number and functionality (14, 15) . Lyn is a Src family member that is mainly involved in down-modulation of several intracellular pathways, including PLCg2 activation (16 
Materials and Methods
Tumor cells and animal models of bone metastases B16 mouse melanoma cells were obtained from Dr. David Fisher (Harvard Medical School). These cells have been characterized by expression arrays and Western blot analysis for melanocyte markers such as melanin, tyrosinase, c-kit, and microphtalmia transcription factor. Pigmented tumor formation in mice further confirmed that B16 are melanoma cells. This assay is routinely used in the laboratory for their characterization and it was conducted within the last few weeks of the experiment. 
DC generation
DCs were generated from bone marrow progenitor cells from 5-to 8-week-old C57BL/6 mice, as previously described (23; Supplementary Data). DCs were matured with 1 mg/mL lipopolysaccharide (LPS) overnight, and upregulation of mature DC markers was confirmed by fluorescence-activated cell sorting (FACS).
T-cell adoptive transfer CD8 þ T cell were magnetically isolated from WT mice vaccinated with GP100 25-33 (10 mg/mL; Bio-Synthesis Inc.) pulsed DCs by using CD8 þ T Cell Isolation Kit (Miltenyi Biotec). Reactivity of GP100-specific CD8 þ T cells was confirmed in vitro by IFN-g release following peptide stimulation. A sample of 1 Â 10 6 CD8 þ T cells plus 200 mL of interleukin (IL)-2 (2,000 U/mL; Chemicon) were adoptively transferred into tumor-bearing (IT-injected) PLCg2 À/À mice via tail vein.
Subsequently, GP100 [25] [26] [27] [28] [29] [30] [31] [32] [33] peptide-pulsed (4 hours), LPSmatured DCs were s.c. administered on the day of the adoptive transfer to further activate GP100-specific CD8 þ T cells.
Tumor-bearing WT and PLCg2 À/À mice receiving IL-2 alone were used as controls. Tumor growth was monitored on days 8, 10, and 12 by bioluminescence imaging (BLI).
Detection of GP100 [25] [26] [27] [28] [29] [30] [31] [32] [33] 
Spleens were isolated from B16-FL s.c. injected mice. Splenocytes were cultured with 10 mg/mL GP100 [25] [26] [27] [28] [29] [30] [31] [32] [33] peptide, in the presence of Golgistop (Becton Dickinson), to inhibit cytokine secretion. After 8 hours, samples were stained with a-CD8-fluorescein isothiocyanate (FITC) Ab (Becton Dickinson), fixed, permeabilized using Cytofix/Cytoperm Kit (Becton Dickinson), co-stained with R-phycoerythrin (PE)-conjugated a-IFN-g Ab, and analyzed by FACS.
Cytometric bead array
A sample of 5 Â 10 4 splenocytes from B16-FL s.c.-injected mice was plated in a 96-well/plate with 200 mL of RPMI-1640 and 10% mouse serum. Cells were restimulated with irradiated B16-FL (2,500 rads) for 3 days. Supernatants were harvested and IFN-g production was assessed by FACS analysis using the T H 1/T H 2 Assay Kit (Becton Dickinson) according to the manufacturer's instructions.
Statistical analysis
For each in vivo experiment, 4 to 6 mice per group were used. Experiments were done in triplicate and analyzed using Student's t-test. In calculating 2-tailed significance levels for equality of means, equal variances were assumed for the 2 populations. Results were considered significant at P < 0.05, and are indicated with an asterisk (*).
Results

PLCg2
À/À mice have increased bone tumor burden despite defective OC function Deletion of PLCg2 in mice results in an osteopetrotic phenotype due to OC defects (14, 15) . Based on the tumor/ bone vicious cycle model in which OC activity is required to sustain tumor growth in bone, we predicted that PLCg2 and tumor cells (T). C, histologic analysis of tumor area/total bone area showed a significant increase in tumor growth in PLCg2 À/À mice (*, P < 0.05 vs. WT)
despite decreased OC number/bone perimeter (D; *, P < 0.05 vs. WT). E, bone loss was calculated as the percentage of BV/TV relative to tumor-free controls (CTR). Although WT mice underwent 50% bone loss after tumor injection, only less than 20% bone loss occurred in PLCg2 À/À mice (*, P < 0.05 vs.
WT). F, increased bone loss in WT mice was further confirmed by higher CTX levels. Data are expressed as fold induction from baseline, arbitrarily set as 1, and significant lower CTX levels in PLCg2 À/À mice are indicated (*, P < 0.05 vs. WT; n ¼ 5 for WT and n ¼ 4 for PLCg2
These results were also replicated using non-labeled parental B16 cells (data not shown), indicating that the presence of the luciferase was not responsible for the altered tumor growth. Interestingly, consistent with impaired basal osteoclastogenesis, tumor-bearing PLCg2 À/À animals continued to display a 3-fold decrease in OC number compared with equally treated WT littermates (Fig. 1D) . Despite the increase in tumor burden, PLCg2 À/À mice were still protected from tumorassociated bone destruction as determined by more than 80% of remaining trabecular BV/TV relative to their tumorfree controls. In contrast, tumor-bearing WT mice displayed approximately 50% reduction in BV/TV (Fig. 1E) . Decreased tumor-associated bone erosion in PLCg2 À/À mice was further confirmed by low serum levels of Collagen type I fragment (CTX), a marker of in vivo OC activity (Fig. 1F) . Thus, our data show that OC deficiency is not sufficient to prevent tumor growth in bone of PLCg2 À/À mice. (17-19). In contrast to PLCg2 À/À animals, Lyn À/À mice displayed significant inhibition of tumor growth in bone following either intratibial or intracardiac tumor inoculation ( Fig. 3A and B). Analysis of tumor area/total bone area confirmed a 4-fold decrease in tumor burden in Lyn À/À mice (Fig. 3C ).
Increased bone tumor burden in
However, despite the significantly reduced bone tumor burden, Lyn À/À mice had increased OC numbers and showed as much tumor-associated bone loss as WT mice ( Fig. 3D and E) . Consistent with this finding, Lyn À/À mice had elevated serum CTX levels (Fig. 3F ). These data indicated that increased OC responsiveness is not sufficient to enhance tumor growth in bone of Lyn À/À mice.
Reduction in bone tumor burden in Lyn À/À is transplantable To determine whether cells of the hematopoietic compartment were responsible for reduced bone tumor burden in Lyn À/À mice, we carried out bone marrow transplants, in which WT recipient mice carried WT (WT > WT) or Lyn À/À (Lyn À/À > WT) marrow cells. We found that Lyn À/À > WT transplanted animals were protected from B16-FL tumor growth in bone, as determined by BLI (Fig. 4A ) and histologic analysis (Fig. 4B ). Similar to Lyn À/À mice, Lyn À/À > WT transplants displayed disproportionate bone loss for their tumor burden, showing similar OC number and percentage of BV/TV as WT > WT transplants despite the 4-fold decrease in bone tumor burden ( Fig. 4C-E) . Due to the hyperactive Lyn À/À OC phenotype, these data indicate that cells of hematopoietic origin, other than OCs, contribute to reduced tumor growth in bone of Lyn À/À mice.
Modulation of T-cell activation alters tumor burden in bone independent of OC activity T cells are known to be modulators of antitumor immune responses (24) . To determine whether T cells might be regulating tumor growth in bone, we injected WT mice with the a-CTLA4 Ab, which enhances T-cell proliferation and/or function (25) , following intracardiac inoculation of B16-FL. a-CTLA4 Ab significantly suppressed tumor growth in bone, as shown by BLI and histomorphometric analysis ( Fig. 5A and  B) . Conversely, Nude mice, which lack all T-cell subsets, had enhanced tumor growth in bone compared with control animals (Fig. 5C ). Histologic analysis confirmed an abundance of tumor cells in the bones of Nude mice compared with their controls (Fig. 5D ). To determine which T-cell subset might be regulating tumor growth in bone, we turned to MHCI À/À mice, which do not have CD8 þ T cells, and MHCII À/À mice, which lack CD4 þ T cells. Absence of either CD4 þ or CD8 þ T cells significantly increased B16-FL tumor growth in bone following intracardiac inoculation. MHCI À/À mice had >4-fold increase and MHCII À/À mice had >2.5-fold increase in bone tumor burden by day 10 as compared with WT mice (Fig. 5E and F) . Because the tumor/bone vicious cycle model considers OC activity to be central to tumor proliferation in bone, we sought to determine the relative contribution of OCs and T cells in this process. We tested the efficacy of ZOL antiresorptive WT mice; n ¼ 6), despite (D) increased OC numbers (*, P < 0.05 vs. WT mice; n ¼ 6; insert 2.5Â magnification) and (E) 50% bone loss calculated as percentage BV/TV relative to tumor-free controls (CTR). F, CTX serum levels showed higher OC activity in Lyn À/À mice compared with WT (*, P < 0.05 vs. WT mice; n ¼ 5 for WT and n ¼ 4 for Lyn photons/s) treatment in providing protection from tumor growth in bone in mice depleted of CD4 þ or CD8 þ T cells. WT mice were treated with ZOL 10 and 4 days before B16-FL intratibial inoculation, and a-CD4 þ or a-CD8 þ T-cell-depleting Abs were administered 1 day before and every 2 days after injection of cancer cells. Efficiency of T-cell depletion was confirmed at the end of the experiment by FACS analysis. Despite blockade of tumor-associated bone loss (Supplementary Data 1), we found that the antitumor effect of ZOL was significantly reduced in CD8 þ , and to a lesser extent in CD4 þ , T-celldepleted mice compared with WT mice receiving the antiresorptive treatment ( Fig. 5G and H) . Thus, T cells modulate tumor growth in bone regardless of the OC status. (Fig. 6A) . Furthermore, IFN-g release was observed in response to parental B16 cells (data not shown). To further determine whether the antitumor T-cell response was specific to the B16 cell line, splenocytes isolated from tumor-bearing mice were stimulated for 8 hours with tumor antigen GP100, expressed by B16 cells. FACS analysis showed that the percentage of CD8 þ /IFN-g producing PLCg2 À/À T cells responding to GP100 was significantly less than those in WT mice, whereas in Lyn À/À mice it was 2-fold more than that in WT mice (Fig. 6B) , supporting the conclusion that PLCg2 À/À and Lyn À/À mice have altered T-cell responses to tumor. To further determine whether T-cell abnormalities were responsible for increased bone tumor burden in PLCg2 À/À mice, we adoptively transferred tumor-specific cytotoxic CD8 þ T cells into PLCg2 À/À mice. Because B16 melanoma cells express the antigen GP100, we generated GP100-reactive CD8 þ T cells by injecting twice GP100 [25] [26] [27] [28] [29] [30] [31] [32] [33] Fig. 6C and D) . Conversely, Ab-mediated CD8 þ T-cell depletion in tumor-bearing Lyn À/À mice enhanced tumor burden in bone by BLI, although CD4 þ depletion did not cause increased tumor burden (Fig. 6E) . To simultaneously measure tumor burden and confirm CD4/CD8 depletion, we conducted FACS analysis on tumor-bearing bones and found that CD8 þ depletion led to more tumor growth in bone marrow, as determined by TRP-1 þ staining, a surface marker of B16 cells (Fig. 6F ). 
Discussion
Animal studies using human breast cancer cells injected in immunocompromised mice strongly support a tumor/bone vicious cycle model in which blockade of OC function can reduce tumor growth in bone and prevent associated bone loss (26, 27) . ZOL, a potent inhibitor of OC activity, is widely used in the clinic to treat patients with bone metastases. ZOL confers protection from tumor-induced bone loss and reduces skeletal complications such as bone pain, pathologic fractures, bone surgery, and hypercalcemia. Unfortunately, one third of patients with bone metastases who respond to ZOL treatment develop further skeletal-related events within 2 years of initiating the antiresorptive therapy (5). Therefore, the tumor/ bone vicious cycle model must be revisited to include other bone marrow-derived cells, in addition to the OCs that can participate in restraining or encouraging the expansion of tumor in the bone microenvironment, thus altering the efficacy of antiresorptive therapies. By using immunocompetent mice, we showed that alterations in T-cell functions can bypass the requirement for OCs in tumor growth within bone and reduce the efficiency of ZOL treatment.
PLCg2 plays a critical role in bone homeostasis and immune function (12, 13, 15, 23, (28) (29) (30) . Previous studies using a tumorrejection assay, in which MHCI-deficient susceptible target cells were injected intraperitoneally in WT or PLCg2 (18, 19, 32, 33) . In agreement with a hyperactive Despite not being expressed in T cells, both PLCg2 and Lyn indirectly govern T-cell activation by modulating myeloid cell functions. Defective DC-mediated antigen presentation (13, 23) probably underlies the reduced number of tumor-specific CD8 þ T cell in PLCg2 À/À mice. Because of impaired DC functions, PLCg2 À/À mice are protected from antigen-induced arthritis, an inflammatory condition strongly dependent on Tcell activation (23) . It is very likely that DC defects impair T-cell activation in PLCg2 À/À tumor-bearing mice, thus enhancing bone tumor burden even in the absence of functional OCs. An additional explanation for the tumor phenotype in PLCg2 À/À mice could be defective NK-cell cytotoxicity (12) . It is unlikely that NK-cell abnormalities are primarily responsible for increased tumor growth in these mice, because NK-cell depletion in WT mice can only slightly increase bone tumor burden without reaching the levels observed in PLCg2 À/À animals (Supplementary Data 5). Conversely, Lyn À/À mice have expanded macrophage and DC populations (18, 36) as well as hyperactive myeloid cells that augment T-cell responses and IFN-g production (19) . Indeed, we found that tumor-bearing Lyn À/À mice display increased tumor-antigen-specific CD8 þ T cells in spleen compared with WT. Therefore, similar to PLCg2 deficiency, absence of Lyn in the myeloid population is likely to be responsible for enhanced T-cell antitumor responses.
To the best of our knowledge, this report is the first to analyze the relative contribution of bone and immune cells in development of bone metastases. We now provide compelling evidence that a condition of immune deficiency can interfere with the antitumor effects of OC blockade. We used both genetic models of immune and OC modulation (Lyn and PLCg2), as well as pharmacologic inhibition of OCs and T cells. These findings suggest that the immune status can affect the efficacy of antiresorptive treatments in reducing bone metastases and emphasize the need to further explore the beneficial effects of combined T-cell stimulation and antiresorptive therapies in patients with bone metastases.
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